Detail of the session
Type :
DISCUSSED E-POSTERS
DISCUSSED E-POSTERS
Date :
Thursday 25th April 2019
Thursday 25th April 2019
Schedule :
16h10 - 16h25
16h10 - 16h25
Session Title :
E-Posters Discussion - Counter 1
Room :
E-POSTERS' AREA
P032
16h10 - 16h15
16h10 - 16h15
SAFETY OF CERTOLIZUMAB PEGOL IN PLAQUE PSORIASIS: POOLED 96-WEEK DATA FROM THREE PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDIES (CIMPASI-1, CIMPASI-2 AND CIMPACT)
Andrew BLAUVELT - United States
Andrew BLAUVELT - United States
P031
16h15 - 16h20
16h15 - 16h20
EFFICACY OF SWITCHING TO RISANKIZUMAB COMPARED WITH CONTINUED ADALIMUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Caitriona RYAN - Ireland
Caitriona RYAN - Ireland
P030
16h20 - 16h25
16h20 - 16h25
HIGH AND DURABLE CLEARANCE THROUGH 52 WEEKS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Melinda GOODERHAM - Canada
Melinda GOODERHAM - Canada